Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Keywords

Denosumab, Medicine, RANKL, Osteoporosis, Bone resorption

References

• Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisJean‐Yves Reginster, H. W. Minne, O. H. Sørensen — 2000
• Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF)Stuart L. Silverman, Steven R. Cummings, Nelson B. Watts — 2007
• Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal OsteoporosisJ. Timothy Harrington, L.-G. Ste-Marie, Maria Luisa Brandi — 2004
• Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.Steven T. Harris, Nelson B. Watts, Rebecca D. Jackson — 1993
• Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMDE. Michael Lewiecki, Paul D. Miller, Michael R. McClung — 2007
• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.Dennis M. Black, Pierre D. Delmas, Richard Eastell — 2007
• The long and the short of bone therapy.Michael P. Whyte — 2006
• Osteoporosis Panel SummaryA M Capron, Sue Donaldson, Lawrence G. Raisz — 2003
• Vertebral fracture assessment using a semiquantitative techniqueHarry K. Genant, Chun‐Ying Wu, Cornelis van Kuijk — 1993
• Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.Ethel S. Siris, Steven T. Harris, Clifford J. Rosen — 2006
• Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 TrialJacques P. Brown, Richard L. Prince, Chad Deal — 2009
• Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A PerspectiveMary Bouxsein, Pierre D. Delmas — 2008
• Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosisAnthony Sebba, Sydney Lou Bonnick, Risa Kagan — 2004
• Osteoclast differentiation and activationWilliam J. Boyle, W. Scott Simonet, David L. Lacey — 2003
• Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisCharles H. Chesnut, Arne Skag, Claus Christiansen — 2004
• Epidemiology and outcomes of osteoporotic fractures.Steven R. Cummings, L. Joseph Melton — 2002
• An estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOlof Johnell, J. A. Kanis — 2006
• Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.George A. Wells, Ann Cranney, Joan Peterson — 2008
• Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.Steven T. Harris — 1999
• Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyR.G.G. Russell, Nelson B. Watts, Frank H. Ebetino — 2008

Cited by

• First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI.Oliver Semler, Christian Netzer, Heike Hoyer‐Kuhn — 2012
• Molecular and cellular basis of bone resorptionReinhard Gruber — 2015
• Should we really compare absolute risk reduction in different trials on osteoporosis: comment on the article by Ringe JD and Doherty JGJuan Bautista Martín Queralt — 2011
• Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?Hannah Allerdice — 2011
• Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal womenon behalf of the DAPS Investigators, Nick Freemantle, Sacha Satram‐Hoang — 2011
• [Denosumab for treatment of postmenopausal osteoporosis].Will Fitzhugh — 2011
• Individualizing osteoporosis therapyFabio Zanchetta — 2012
• Development and Function of Murine B Cells Lacking RANKLucía Pérez-Castilla Álvarez — 2012
• Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces真也 伊藤, 知行 赤堀, 祥二 川人 — 2013
• Pharmacologic management of osteoporosis.Časlav Pejović — 2014
• Assessment and management of fracture risk in patients with Parkinson's disease.浩雄 佐々木 — 2015
• Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)Timothy Price — 2015
• Sustained Modeling‐Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With DenosumabMichael S. Ominsky, Cesar Libanati, Qing‐Tian Niu — 2015
• Denosumab versus zoledronic acid in patients previously treated with zoledronic acid聖子 飯降, 次郎 藤田, 宏泰 矢島 — 2015
• Overdiagnosis and Overtreatment of Osteoporosis: A Wolf in Sheep's ClothingMatthew D. Shaw — 2015
• Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis清 古川 — 2016
• Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients李丽梅, 周箐 — 2017
• Treatment of osteoporosis: current state of the artIrene Hamrick, Sarina Schrager, Ann Marie Nye — 2015
• Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.Gwenaël Fubiani — 2017
• Osteoporosis in mineral and bone disorders of chronic kidney disease.Tomasz Stompór, Marek Zabłocki, Mirosław Łesiów — 2013

Related papers

• Inhibition of RANKL: a new approach to the treatment of osteoporosisSheila A Doggrell — 2006
• Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis.Neveen A. T. Hamdy — 2007
• The Basics of Bone Physiology, Healing, and Osteoporosis.John R. Dimar, Joseph M. Lane, Ronald A. Lehman — 2021
• [Anti-RANKL monoclonal antibody Denosumab (AMG162)].Toshitsugu Sugimoto — 2011
• New Horizons in OsteoporosisTilman D. Rachner, Sundeep Khosla, Lorenz C. Hofbauer — 2011
• Роль цитокиновой системы rankl-rank-opg и катепсина к в патогенезе остеопороза: достижения и перспективы в лечении заболеванияS. Sagalovsky, P. Kunze, Matthias Schоnert — 2015
• Increasing Options for the Treatment of OsteoporosisSundeep Khosla — 2009
• Denosumab and bisphosphonates: different mechanisms of action and effects.Roland Baron, Serge Ferrari, R.G.G. Russell — 2011
• New therapies in osteoporosisAndrés Felipe Posada, Hernán Darío Aguirre, Julio César García Casallas — 2016
• [A new treatment for osteoporosis using fully human monoclonal antibody to RANKL, AMG 162].Naoyuki Takahashi, Hidehiro Ozawa — 2005